Short answer
DiaMedica Therapeutics Inc. (DMAC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$11M
- −31.2% YoY · −11.5% QoQ
- EPS (diluted)
- −$0.20
- −17.6% YoY · −5.3% QoQ
Source: XBRL data from the DiaMedica Therapeutics Inc. (DMAC) Q3 2026 10-Q on SEC EDGAR. USD.
DiaMedica Therapeutics Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- R&D expenses $9.2M vs $6.4M YoY, G&A expenses $2.4M vs $2.6M
- Net loss $31.5M for nine months vs $24.0M YoY, no margin figures disclosed
- Cash, equivalents and securities $34.9M vs $59.9M at December 31, 2025
- ReMEDy2 enrollment slower than expected, interim results expected by end of Q1 2027; additional funding anticipated
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Carried-forward risk: unknown or currently immaterial risks could impair business, financial condition, or results of operations
- Carried-forward disclosure: existing uncertainties could cause actual results to differ materially from forward-looking statements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DiaMedica Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.